title: Suprasellar germinomas in childhood. A reappraisal.
abstract: Germinomas in childhood may arise in both the suprasellar and pineal region, and outcome has been reported to be worse for suprasellar germinomas with a 5-year survival rate of 20% as compared to 60% for pineal germinoma. To determine the factors impacting on outcome, the results of a uniform treatment approach were evaluated and included primary surgical debulking (PSD) and systemic craniospinal axis radiation (CSRT) for suprasellar germinomas. Between 1976 and 1985 ten consecutive patients (seven females, three males) with the pathologically confirmed diagnosis of suprasellar germinoma were treated. Outcome was compared to four male patients with pineal germinoma treated over the same time period and series of patients reported in the literature. At diagnosis the mean age of patients with suprasellar germinoma was 13.9 years (range, 8.9 to 9.4 years). Symptoms were present for a mean of 18 months (range, 2 to 72 months) prior to diagnosis and included diabetes insipidus, anterior pituitary dysfunction, decreased vision, headache, vomiting, and diplopia. Staging studies, including myelography (n = 4) and cerebrospinal fluid cytology (n = 7), disclosed dissemination in only one child. Surgical treatment included biopsy in three cases, partial resection in five, and total resection in two; no permanent postsurgical complications were noted. The mean radiation therapy dose to the tumor site was 4953 cGy (range, 4400 to 5250 cGy) and to the spine 3354 cGy (range, 3000 to 4000 cGy). Patients were followed for a mean period of 5.1 years (range, 1.9 to 10.5 years). One patient with SG who did not receive treatment initially developed a pineal tumor after diagnosis; she was treated with PSD and CSRT and is asymptomatic 5 years later. All the remaining patients are alive and remain disease-free. Surgical resection and CSRT results in excellent disease control for children with suprasellar germinomas, and outcome is similar to those patients with pineal germinoma.
authors.affiliation: Neuro-Oncology Program, Children's Hospital, Philadelphia, PA 19104.
authors.forename: A
authors.initials: A
authors.lastname: Legido
authors.forename: R J
authors.initials: RJ
authors.lastname: Packer
authors.forename: L N
authors.initials: LN
authors.lastname: Sutton
authors.forename: G
authors.initials: G
authors.lastname: D'Angio
authors.forename: L B
authors.initials: LB
authors.lastname: Rorke
authors.forename: D A
authors.initials: DA
authors.lastname: Bruce
authors.forename: L
authors.initials: L
authors.lastname: Schut
mesh_terms: D000293:Adolescent; D001932:Brain Neoplasms / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D002648:Child; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D010870:Pineal Gland / Q000000981:diagnostic imaging / Q000473:pathology; D010871:Pinealoma / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D010911:Pituitary Neoplasms / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D011379:Prognosis; D011859:Radiography